GRL-0617 |
識別資訊 |
---|
5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide
|
CAS號 | 1093070-16-6 Y |
---|
PubChem CID | |
---|
IUPHAR/BPS | |
---|
DrugBank | |
---|
ChemSpider | |
---|
UNII | |
---|
ChEBI | |
---|
ChEMBL | |
---|
化學資訊 |
---|
化學式 | C20H20N2O |
---|
摩爾質量 | 304.39 g·mol−1 |
---|
3D模型(JSmol) | |
---|
CC1=C(C=C(C=C1)N)C(=O)N[C@H](C)C2=CC=CC3=CC=CC=C32
|
InChI=1S/C20H20N2O/c1-13-10-11-16(21)12-19(13)20(23)22-14(2)17-9-5-7-15-6-3-4-8-18(15)17/h3-12,14H,21H2,1-2H3,(H,22,23)/t14-/m1/s1 Key:UVERBUNNCOKGNZ-CQSZACIVSA-N
|
GRL-0617是一種藥物,是最早被發現可作為木瓜蛋白酶樣蛋白酶的選擇性小分子抑制劑的化合物之一,它可在某些致病病毒(包括冠狀病毒SARS-CoV-2)中發現。它已被證明可以在體外抑制病毒複製。[1][2][3][4]
參考文獻[編輯]
- ^ Shin D, Mukherjee R, Grewe D, Bojkova D, Baek K, Bhattacharya A, et al. Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity. Nature. November 2020, 587 (7835): 657–662. Bibcode:2020Natur.587..657S. PMC 7116779 . PMID 32726803. doi:10.1038/s41586-020-2601-5.
- ^ Hajbabaie R, Harper MT, Rahman T. Establishing an Analogue Based In Silico Pipeline in the Pursuit of Novel Inhibitory Scaffolds against the SARS Coronavirus 2 Papain-Like Protease (PDF). Molecules. February 2021, 26 (4): 1134 [2022-12-12]. PMC 7924369 . PMID 33672721. doi:10.3390/molecules26041134 . (原始內容存檔 (PDF)於2022-12-12).
- ^ Lim CT, Tan KW, Wu M, Ulferts R, Armstrong LA, Ozono E, et al. Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp3 papain-like protease. The Biochemical Journal. July 2021, 478 (13): 2517–2531. PMC 8286840 . PMID 34198325. doi:10.1042/BCJ20210244.
- ^ Xiang R, Yu Z, Wang Y, Wang L, Huo S, Li Y, et al. Recent advances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharmaceutica Sinica. B. July 2021. PMC 8260826 . PMID 34249607. doi:10.1016/j.apsb.2021.06.016.